NorthWest Biotherapeutics Inc (NWBO)

[User-840664]

To demonstrate that the efficacy of the new DCVax-L-based therapy provides additional benefits in comparison to the standard of care, the results reported by Liau et al. should be confirmed by a randomised trial. Further studies should also evaluate the effect of the DCVax-L vaccine in combination with other standard systemic therapies routinely used for the treatment of GB. Considering the challenges encountered during the planning of clinical studies for newly diagnosed GB without accounting for the cross-over effect after progression, recurrent GB that were not previously treated with the DCVax-L vaccine could be regarded as the most suitable setting for planning prospective randomised trials. Appropriate novel trial designs, for example, window trials, could be considered.

3-5 more years of trials and another $100 Million needed, IMO


https://www.nature.com/articles/s41416-023-02194-1